Cardiac SARS-CoV-2 infection is associated with distinct tran-

scriptomic changes within the heart

Diana Lindner, PhD^{*1,2⊠}, Hanna Bräuninger, MS^{*1,2}, Bastian Stoffers, MS^{1,2}, Antonia Fitzek, MD³, Kira Meißner³, Ganna Aleshcheva, PhD⁴, Michaela Schweizer, PhD⁵, Jessica Weimann, MS¹, Björn Rotter, PhD⁹, Svenja Warnke, BSc¹, Carolin Edler, MD³, Fabian Braun, MD⁸, Kevin Roedl, MD¹⁰, Katharina Scherschel, PhD^{1,12,13}, Felicitas Escher, MD^{4,6,7}, Stefan Kluge, MD¹⁰, Tobias B. Huber, MD⁸, Benjamin Ondruschka, MD³, Heinz-Peter-Schultheiss, MD⁴, Paulus Kirchhof, MD^{1,2,11}, Stefan Blankenberg, MD^{1,2}, Klaus Püschel, MD³, Dirk Westermann, MD^{1,2⊠}

¹ Department of Cardiology, University Heart and Vascular Center Hamburg, Germany.

² DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck.

³ Institute of Legal Medicine, University Medical Center Hamburg-Eppendorf, Germany.

⁴ Institute for Cardiac Diagnostics and Therapy, Berlin, Germany.

⁵ Department of Electron Microscopy, Center for Molecular Neurobiology, University Medical Center Hamburg-Eppendorf, Germany.

⁶ Department of Cardiology, Charité-Universitaetsmedizin, Berlin, Germany.

⁷ DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany.

⁸ III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Germany.

⁹ GenXPro GmbH, Frankfurter Innovationszentrum, Biotechnologie (FIZ), Frankfurt am Main, Germany.

¹⁰ Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Germany.

¹¹ Institute of Cardiovascular Sciences, University of Birmingham, UK.

¹² Division of Cardiology (cNEP), Evangelisches Krankenhaus Düsseldorf, Germany.

¹³ Institute of Neural and Sensory Physiology, Medical Faculty, Heinrich Heine University Düsseldorf, Germany.

* these authors contributed equally to this work.

Corresponding authors

Dirk Westermann, MD
Phone: +49 40 7410 57507
Fax: +49 40 7410 58862
Email: d.westermann@uke.de

Diana Lindner, PhD
Phone: +49 40 7410 18792
Fax: +49 40 7410 58862
Email: d.lindner@uke.de

University Heart and Vascular Center Hamburg Department of Cardiology Martinistr. 52, 20246 Hamburg, Germany

1 Expanded Material and Methods

1.1 RNA isolation and reverse transcription

To isolate total RNA, snap frozen cardiac tissue was added to QIAzol (Qiagen, Germany) and immediately disrupted in the tissue lyser II (Qiagen, Germany). Using the miRNeasy mini kit (Qiagen, Germany), RNA was further purified following the manufacturer's protocol. As suggested, DNase I (Qiagen, Germany) was applied to the column to avoid genomic DNA contamination. RNA concentration was measured on a Nanodrop 2000c spectrophotometer. Until further processing, RNA was stored at -80 °C. The synthesized complementary DNA (cDNA) was diluted to a final concentration of 10 ng/µl prior to Taq-Man analyses.

1.2 Gene expression analysis – TaqMan PCR

Quantitative TaqMan PCR was performed on a QuantStudio7 system (Thermo Fisher Scientific, USA) with 2.5 μ l gene expression master mix (Thermo Fisher Scientific, USA) and 0.25 μ l specific gene expression assay. Gene expression assays, including forward and reverse primers as well as the FAM-labelled probe, are listed in the Supplemental Table S1. cDNA samples were analyzed in duplicates. Due to the low gene expression of *ACE2* and *TMPRSS2*, some samples revealed no Ct value for these target genes. In these cases, the Ct value was set to 40 for subsequent calculations. The Ct value of the housekeeping gene *CDKN1b* was used to calculate Δ Ct values of the target genes. The median Δ Ct value of the group without cardiac infection was used to quantify the gene expression using the formula 2^{- $\Delta\Delta$ Ct} and plotted as relative gene expression x-fold to "no cardiac infection".

Assay	Gene name	Ordering number	
ACE2	Angiotensin-converting enzyme 2	Hs00222343_m1	
TMPRSS2	Transmembrane protease serine 2	Hs01122322_m1	
CTSB	Cathepsin B	Hs00947439_m1	
CTSL	Cathepsin L	Hs00964650_m1	
CDKN1b	Cyclin-dependent kinase inhibitor 1B	Hs00153277_m1	

Supplemental Table S1: Gene expression assays purchased from Thermo Fisher Scientific.

1.3 Histological analyses

Left ventricular tissue was fixed in 10% neutral-buffered formalin for at least 48 h at room temperature (RT), subsequently dehydrated and embedded in paraffin. Four micrometer-thick sections were cut and deparaffinized using xylene substitute (Roti-Histol, Germany) and rehydrated in a descending ethanol series. After dehydration, slides were mounted in Eukitt (Sigma-Aldrich, USA).

To characterize and quantify inflammatory infiltrates, FFPE tissue sections underwent a heat-induced antigen retrieval using citrate butter (pH 6). For detection of immune cell-specific markers, the primary

antibodies used are listed in the Supplemental Table S2. As secondary antibody, we used enhancing EnVision[™] peroxidase-conjugated anti-mouse antibody (DakoCytomation, Germany). Immunohistological staining was visualized using 3-amino-9-ethylcarbazole (Merck, Germany) as chromogenic substrate. Finally, slides were counterstained in haematoxylin and mounted with Kaiser's gelatine (Merck, Germany). Immunoreactivity was quantified by digital image analysis (DIA) as described previously.¹

nouse	1.25		
nouse	1.25		
	1.25	Agilent	M7254
nouse	1:50	Medac	108M-94
nouse	1:100	Agilent	M0876
nouse	1:300	Agilent	M0742
abbit	1:30	Cell Signaling	3134
lonkey	1:500	Thermo Fisher	A-21206
r r	nouse nouse nouse abbit onkey	nouse 1:50 nouse 1:100 nouse 1:300 abbit 1:30 onkey 1:500	nouse 1:50 Medac nouse 1:100 Agilent nouse 1:300 Agilent abbit 1:30 Cell Signaling onkey 1:500 Thermo Fisher

Supplemental Table S2: Primary antibodies used for immunohistological or immunofluorescence analyses.

In case of fluorescence staining, heat-induced antigen retrieval was performed using citrate buffer (pH 6). Subsequently, sections were permeabilized in 0.2% Triton X-100/tris-buffered saline (TBS) for 10 min and autofluorescence was quenched with the help of 0.25% Sudan black/70% ethanol for 30 min. Before application of primary antibodies (see Supplemental Table S2) over night at 4 °C, sections were blocked with 3% bovine serum albumin (BSA)/TBS for 2 h at RT. The secondary antibody listed in the Supplemental Table S2 was incubated for 2 h RT. After washing in TBS, slides were mounted in DAPI Fluoromount-G (SouthernBiotech, USA).

1.4 RNA in situ hybridization

For detection of SARS-CoV-2 plus and minus strand, RNAscope in situ hybridization was performed using chromogenic staining or fluorescent staining on FFPE tissue sections. For chromogenic staining, RNAscope[®] 2.5 HD Reagent Kit-RED (#322350; Advanced Cell Diagnostics (ACD), USA) was used, whereas for localization studies, RNAscope Multiplex Fluorescent v2 reagent kit (#323100, ACD, USA) was used. After deparaffinization, target retrieval was performed for 15 min, followed by quenching of internal peroxidase activity and permeabilization by protease plus treatment for 30 min at 40°C. The hybridization of target specific probe (see Supplemental Table S3), subsequent amplification steps and signal detection were performed as described in manufacturer's instructions. For chromogenic staining, nuclei were counterstained using hematoxylin. In case of fluorescent staining, lipofuscin autofluo-rescence was quenched via Sudan black staining (0.25% in 70% ethanol) for 8 min, followed by a block-ing step (1% BSA/TBS for 1 h at RT) and subsequent counterstaining with Alexa-coupled wheat germ

agglutinin (WGA, 1:500) and bisbenzimide H33342 trihydrochloride (Hoechst, 1:1000) for 1 h in blocking solution. Matching negative controls for chromogenic and fluorescent staining are shown in the Supplemental Figures S1 and S2, respectively.

Supplemental Table 55. Probes used for in situ hybridization (KNAScope).			
Probe	Company	Ordering information	
RNAscope [®] Probe- V-nCoV2019-S	ACD	848561	
RNAscope [®] Probe- V-nCoV2019-S-sense	ACD	845701	
RNAscope [®] Positive Control Probe- Hs-UBC	ACD	310041	
RNAscope [®] Negative Control Probe- DapB	ACD	310043	

Supplemental	Table S3: Probes	used for in situ	hvbridization	(RNAscope)
Supprementar	10010 00.1100000		a ny shaiza cion	(Intracope)

1.5 Microscopy

Images of non-fluorescently stained tissue including chromogenic RNAscope staining were taken using a Keyence BX-9000 microscope equipped with ×20 plan APO (NA = 0.75) and ×60 plan APO oil (NA = 1.40) objectives. After immunofluorescence staining and fluorescent RNAscope, confocal images were captured using a Leica TCS SP5 confocal microscope (Leica Microsystems) equipped with ×40 HCX PL APO CS oil (NA = 1.3) and ×63 HCX PL APO Lbd. Bl. oil (NA = 1.4-0.6) objectives. Three-dimensional images were collected and a maximum projection image was created using the Leica LAS AF software.

2 Expanded Results

2.1 Expanded baseline information

The extended baseline table (Supplemental Table S4) provides further information concerning case characteristics and data availability. The added category, location of death, is grouped in four classifications: domesticity, nursing home, normal care, and intensive care. Furthermore, all characteristics for the groups analyzed by 3'mRNA sequencing are listed. To improve RNA quality for 3'mRNA sequencing, patients died in hospital and with post mortem intervals of maximal five days were chosen. However, the cases represent the entire study cohort regarding the categories age, sex, time between diagnosis and death, comorbidities and BMI.

Supplemental Table S4: Extended baseline characteristics.

		Cases grouped by cardiac virus load or replication			Cases analyzed by 3'mRNA sequencing				
		Cardiac infec-		Cardiac infec-					
	All	No cardiac in-	tion		Virus replication		No cardiac in-	tion	
	cases	fection	(> 1000 copies)		(scored >1)		fection	(>1000 copies)	
				p-		p-			p-
	(N=95)	(N=46)	(N=41)	value*	(N=14)	value*	(N=10)	(N=10)	value ⁺
Female No. (%)	51 (53.7)	21 (45.7)	24 (58.5)	0.32	7 (50.0)	1.00	5 (50.0)	7 (70.0)	0.65
Available data No. (%)	95 (100)	46 (100)	41 (100)		14 (100)		10 (100)	10 (100)	
Age [years]	84.0 (76.0, 87.0)	81.5 (74.2, 86.0)	84.0 (78.0, 88.0)	0.27	86.0 (82.5, 87.8)	0.13	82.5 (78.2, 84.0)	84.5 (79.8, 86.5)	0.34
Available data No. (%)	95 (100)	46 (100)	41 (100)		14 (100)		10 (100)	10 (100)	
Post mortem interval [days]	4.0 (3.0, 7.0)	4.0 (2.0, 6.0)	4.0 (3.0, 8.0)	0.38	5.0 (3.0, 9.8)	0.17	4.0 (1.5, 4.0)	3.5 (2.2, 4.8)	0.79
Available data No. (%)	93 (97.9)	45 (97.8)	40 (97.6)		14 (100)		10 (100)	10 (100)	
Location of death:									
Domesticity No. (%)	10 (11.1)	7 (15.9)	3 (7.9)	0.44	0 (0)	0.29	0 (0)	0 (0)	
Nursing home No. (%)	24 (26.7)	7 (15.9)	12 (31.6)	0.16	5 (38.5)	0.17	0 (0)	0 (0)	
Normal Care No. (%)	32 (35.6)	15 (34.1)	16 (42.1)	0.60	8 (61.5)	0.15	5 (50.0)	8 (80.0)	0.35
Intensive care No. (%)	23 (25.6)	14 (31.8)	7 (18.4)	0.26	0 (0)	0.048	5 (50.0)	2 (20.0)	0.35
Available data No. (%)	90 (94.7)	44 (95.7)	38 (92.7)		13 (92.9)		100 (100)	100 (100)	
Time, diagnosis until death [days]	9.0 (3.0, 18.0)	12.5 (7.2, 20.2)	8.0 (2.0, 10.0)	0.082	2.0 (2.0, 9.0)	0.017	12.0 (5.5, 19.5)	8.0 (2.0, 10.0)	0.43
Available data No. (%)	55 (57.9)	26 (56.5)	25 (61.0)		9 (64.3)		7 (70.0)	9 (90.0)	
Comorbidities									
HTN No. (%)	44 (46.3)	24 (52.2)	17 (41.5)	0.43	6 (42.9)	0.76	4 (40.0)	5 (50.0)	1.00
CAD No. (%)	58 (61.1)	31 (67.4)	22 (53.7)	0.28	7 (50.0)	0.39	5 (50.0)	4 (40.0)	1.00
HF No. (%)	49 (51.6)	23 (50.0)	22 (53.7)	0.90	8 (57.1)	0.87	4 (40.0)	5 (50.0)	1.00
Sum of cardiac comorbidities ≥2	48 (50.5)	26 (56.5)	18 (43.9)	0.34	8 (57.1)	1.00	2 (20.0)	4 (40.0)	0.63
DM No. (%)	18 (18.9)	11 (23.9)	5 (12.2)	0.26	4 (28.6)	1.00	3 (30.0)	1 (10.0)	0.58
Stroke No. (%)	16 (16.8)	7 (15.2)	7 (17.1)	1.00	5 (35.7)	0.19	2 (20.0)	1 (10.0)	1.00
COPD No. (%)	49 (51.6)	23 (50.0)	24 (58.5)	0.56	10 (71.4)	0.27	2 (20.0)	5 (50.0)	0.35
Cancer No. (%)	29 (30.5)	13 (28.3)	14 (34.1)	0.72	3 (21.4)	0.87	3 (30.0)	7 (70.0)	0.18
Renal failure No. (%)	34 (35.8)	16 (34.8)	17 (41.5)	0.67	8 (57.1)	0.24	2 (20.0)	4 (40.0)	0.63
Sum of non-cardiac comorbidi-	48 (50.5)	22 (47.8)	23 (56.1)	0.58	11 (78.6)	0.086	3 (30.0)	7 (70.0)	0.18
ties ≥2									
Sum of comorbidities ≥2	88 (92.6)	42 (91.3)	38 (92.7)	1.00	14 (100)	0.60	8 (80.0)	10 (100)	0.46
Available data No. (%)	95 (100)	46 (100)	41 (100)		14 (100)		10 (100)	10 (100)	
BMI [kg/m ²]	24.4 (20.7, 28.7)	24.4 (20.9, 28.4)	23.2 (19.1, 28.7)	0.58	25.0 (21.6, 26.8)	0.85	27.4 (25.2, 28.6)	22.4 (20.9, 31.7)	0.57
Available data No. (%)	84 (88.4)	38 (82.6)	39 (95.1)		13 (92.9)		9 (90.0)	10 (100)	

Heart weight [g]	450.0	455.0	420.0	0.40	410.0	0.27	452.5	460.0	0.76
	(361.2, 520.0)	(383.8, 510.0)	(333.8 <i>,</i> 530.0)		(330.0, 505.0)		(407.5, 517.5)	(347.5, 533.8)	
Available data No. (%)	94 (98.9)	46 (100)	40 (97.6)		13 (92.9)		10 (100)	10 (100)	

For continuous variables median (25th percentile, 75th percentile) are given. For binary variables absolute numbers and relative frequencies (%) are given. The presented pvalues were determined by the comparison to all cases with no cardiac infection (N=46)^{*} or to the 10 cases with no cardiac infection used for 3'mRNA sequencing (N=10)[†]. Mann-Whitney test was used for continuous variables and chi-squared test for binary variables. Abbreviations: BMI, body mass index; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HF, heart failure; HTN, hypertension; No, numbers.

2.2 Controls for in situ hybridization

All tissue sections used for in situ hybridization underwent positive and negative controls. As positive control, a probe detecting the mRNA of the ubiquitously expressed Ubiquitin C was used, whereas a probe detecting RNA of the bacterial protein dihydro-dipicolinate reductase (DapB) was used as negative control. The positive control confirmed that the tissue quality enables the detection of RNA, the negative control demonstrate the specificity of the detected signals. Supplemental Figure S1 displays the positive and negative control for case - 08 displayed in Figure 2C in the main manuscript. Supplemental Figure S2 displays the positive and negative controls for the cases used for fluorescent staining depicted in Figure 3 in the main manuscript.



Supplemental Figure S1: Controls for chromogenic RNAscope in situ hybridization.

As positive control of successful chromogenic RNAscope in situ hybridization, probe against Ubiquitin C was used, revealing strong red signals in cardiac tissue. A probe detecting the bacterial gene dihydro-dipicolinate reductase (DapB) was used as negative control and revealed no specific staining.



Supplemental Figure S2: Controls for fluorescent RNAscope in situ hybridization.

A: As positive control of fluorescent RNAscope in situ hybridization Ubiquitin C (red) was used, wheat germ agglutinin (WGA, cyan) was used to counterstain sections.

B: As negative control the bacterial gene dihydro-dipicolinate reductase (DapB, red) was applied on tissue sections. Cell membranes were counterstained with WGA (cyan).

2.3 Olink Data

Olink proteomics performed measurements of 1429 proteins in plasma samples in a cohort of 384 patients including 306 SARS-CoV-2 infected patients and 78 symptomatic controls.² Data were provided by the MGH Emergency Department COVID-19 Cohort (Filbin, Goldberg, Hacohen) with Olink Proteomics. In the present study 824 differently expressed genes in the SARS-CoV-2 infected myocardium were detected. Those were aligned with the 1429 proteins measured by Olink proteomics, resulting in 73 overlapping genes and proteins (Supplemental Figure S3A). The aim of the subsequent analysis was to compare the regulation of these 73 targets on plasma protein and myocardial gene expression level.

Out of all patients included in Olink proteomics analysis, two groups were formed for further analysis (Supplemental Figure S3B). Thus, in the first step all patients with pre-existing heart disease were excluded. Next, all patients classified in WHO category 2 (intubated, ventilated) on day 0 were selected and divided in patients with and without COVID-19. This results in two groups with same disease severity to uncover COVID-19-specific regulated markers.

The plasma protein expression on day 0 of the Olink proteomic study was compared between those groups. Out of the 73 plasma proteins, 20 were upregulated and 3 were downregulated. Overlaps with the significantly up- or downregulated genes were displayed as Venn diagram (Supplemental Figure S3C). Out of the 48 myocardial upregulated genes, 16 were confirmed to be elevated on plasma protein level. However, for downregulated genes this accordance cannot be observed: From 24 downregulated genes in SARS-CoV-2 infected myocardium only one protein is downregulated on plasma protein level. The exact p-values and expression data of those 17 proteins are listed in Supplemental Figure S3D.







D

Protein	Without Covid NPX (Median, IQR)	With Covid NPX (Median, IQR)	p-value	Protein	Without Covid NPX (Median, IQR)	With Covid NPX (Median, IQR)	p-value
AGER	5.1 (4.4, 5.3)	6.4 (5.9, 8.4)	0.0002	HSPB6	4.7 (3.8, 5.9)	3.3 (2.7, 4.5)	0.0042
BST2	3.2 (2.7, 3.9)	5.0 (4.2 <i>,</i> 5.9)	< 0.0001	KRT19	2.3 (1.4, 3.1)	4.7 (3.7, 5.5)	<0.0001
BTN3A2	3.0 (2.6, 3.3)	3.2 (2.9, 3.6)	0.0415	LAP3	2.6 (2.4 ,3.1)	5.0 (4.3, 5.6)	<0.0001
CCL20	5.2 (4.6, 5.4)	5.9 (5.1 <i>,</i> 6.7)	0.0415	MPHOSPH8	0.4 (0.1, 0.8)	0.9 (0.6, 1.3)	0.0173
CD177	3.2 (2.2 <i>,</i> 3.9)	3.7 (3.2 <i>,</i> 4.3)	0.0499	TNFRSF10A	3.4 (2.6, 3.6)	3.7 (3.3, 4.2)	0.0425
CD48	4.3 (4.0, 4.5)	4.7 (4.2 <i>,</i> 5.1)	0.0187	TNFSF14	2.8 (2.2, 3.1)	3.7 (3.4, 4.1)	<0.0001
CTSH	3.0 (2.6, 3.3)	3.6 (3.0, 4.1)	0.0020	TYMP	3.8 (3.2, 5.1)	6.0 (5.4, 6.6)	<0.0001
HPCAL1	4.3 (3.2 <i>,</i> 5.0)	5.0 (4.2 <i>,</i> 5.9)	0.0207	WARS	4.2 (3.9 <i>,</i> 5.4)	6.0 (5.5, 6.3)	<0.0001
HSP1A1	2.0 (1.3, 2.8)	2.4 (2.0, 3.8)	0.0469				

Supplemental Figure S3: Overlaps of significantly regulated genes with proteins measured in the Olink proteomics dataset.

A: Due to SARS-CoV-2 infection of the myocardium, 824 differentially expressed genes were identified in this study and aligned with 1429 proteins measured in the Olink proteomics COVID-19 dataset. 73 overlapping genes and proteins were detected (abbreviations under parenthesis).

B: To identify SARS-CoV-2 specific plasma markers, two groups were formed out of 384 patients. Patients classified in WHO category 2 (intubated and ventilated) on day 0 were selected. These patients were divided in patients without COVID-19 (group 1) and with COVID-19 (group 2). Patients with pre-existing heart diseases were excluded.

C: In red: 48 genes and 20 proteins were identified as upregulated resulting in 16 overlaps upregulated on both gene expression and protein level. In blue: 25 genes and 3 proteins are downregulated resulting in only one overlap, downregulated on both gene expression and protein level.

D: The median and interquartile range (IQR) of the normalized protein expression (NPX) of the two groups defined in B are shown. With the gene expression overlapping proteins are listed. P-values were calculated using the Mann-Whitney test.

2.4 Expanded data from Gene Ontology enrichment analyses

In the presented manuscript, 5 GO circles are displayed. Detailed information and a list of all significantly regulated genes are provided in the following Supplemental Tables S5 - S9.

For the GO circle displayed in Figure 6A, we aimed to present the overall most significant GO terms. But often the significance of parental and child terms is based on the same gene set. For example, the three most significant GO terms in the category biological process include nearly the similar set of genes all involved in interferon signaling (Supplemental Figure S4). Thus, to avoid a list of child terms including the same set of genes, the most specified GO terms within ancestor charts were selected. For this reason, ancestor charts of the 15 most significant GO terms per category were created. Data visualization of ancestor charts was provided by a GenXPro Web application at www.tools.genxpro.net. In the next step, the most descendent child terms including at least 40 annotated genes were selected. The ancestor charts for the three categories biological process, cellular component, and molecular function are depicted in the Supplemental Figures S4, S5, and S6, respectively. The identified GO terms are numbered according to their appearance in Figure 6A.



Supplemental Figure S4: Ancestor Chart created for the 15 most significant GO terms in the category biological process.

The 15 most significant GO terms were displayed as squares, the connected GO terms as circles. The color is defined by the significance illustrating the most significant terms in red.



Supplemental Figure S5: Ancestor Chart created for the 15 most significant GO terms in the category cellular component.

The 15 most significant GO terms were displayed as squares, the connected GO terms as circles. The color is defined by the significance illustrating the most significant terms in red.



Supplemental Figure S6: Ancestor Chart created for the 15 most significant GO terms in the category molecular function.

The 15 most significant GO terms were displayed as squares, the connected GO terms as circles. The color is defined by the significance illustrating the most significant terms in red. For number (7) the parental GO term was selected because in the most significant GO term only 15 genes were annotated.

GO term information	Significantly upregulated genes	Significantly downregulated genes
defense response to virus GO:0051607 Annotated genes: 190	ADAR - BIRC3 - BST2 - DTX3L - EIF2AK2 - GBP1 - IFI44L - IFIT1 - IFIT3 - IRF1 - IRF2 - IRF7 - ISG15 - MUL1 - MX1 - MX2 - OAS3 - PARP9 - PLSCR1 - RNF26	BNIP3 - IL33 - POLR3D
Significant regulated genes: 29 p-value: 1.0 · 10 ⁻⁷	- RSAD2 - STAT1 - TBK1 - TNFAIP3 - TRIM25 - TRIM56	
GO:0002376 Annotated genes: 2376 Significant regulated genes: 170	ADAR - ADD2 - ADGRG3 - AGER - ALDH3B1 - ANXA1 - APOD - APOL1 - AQP4 - ATAD3B - AZI2 - B2M - BCL6 - BIRC3 - BPIFB1 - BRAF - BRCA2 - BST2 - BTN3A2 - C1RL - C3 - CASP4 - CCL20 - CD177 - CD34 - CD48 - CFB - CFD -	ABI1 - ACTN1 - ADA2 - ADGRE5 - ALDOA - ANO6 - AP1S2 - ARID5A - ARPC1A - ATP1B1 - BNIP3 - C6 - CACNA1C - CD63 - CDC73 - CDKN1A - CMKLR1 - COL1A1 - COL1A2 - CYFIP2 - DAPK2 - DSP - EPRS - EPS8 -
p-value: 7.6 · 10 ⁻⁷	CLU - CMTM6 - CREBBP - CSF3 - CSK - CTSH - CXCL1 - CXCL16 - CXCL2 - DCD - DDX3X - DTX3L - EIF2AK2 - ELF2 - EMP2 - EPCAM - GBP1 - GBP4 - GSDMD - HERC6 - HLA-B - HLA-C - HLA-DMA - HLA-DPB1 - HLA-E - HP - HSPA1A - HSPA6 - HSPH1 - ICAM1 - IDH1 - IFI35 - IFI44L - IFI6 - IFIT1 - IFIT3 - IL1R2 - IL6R - INPP5D - IRF1 - IRF2 - IRF7 - ISG15 - LAT2 - LCN2 - LRG1 - LTB - LTBR - MUC1 - MUC5B - MUL1 - MX1 - MX2 - N4BP2L2 - OAS3 - PARP9 - PILRB - PLSCR1 - POU2F2 - PPBP - PSMB9 - RAB34 - RB1 - RHOF - RNF26 - RSAD2 - RUBCN - SBSPON - SECTM1 - SLC2A3 - SLC8B1 - SLPI - SPINK5 - SPN - STAT1 - TAP1 - TBK1 - TF - TMEM190 - TMEM91 - TNFAIP3 - TNFAIP6 - TNFRSF10A - TNFRSF14 - TNFRSF1B - TNFSF10 - TNFSF14 - TRIM25 - TRIM56 - TYROBP - VAMP3 - VEGFD - XAF1	ERAP1 - EXOSC9 - FKBP1A - FN1 - FUCA2 - GAPDH - HK1 - HSPA9 - IL33 - INPPL1 - LTF - LYZ - MB - NPPA - POLR3D - PPP1R14B - PRDX6 - PRKRA - RAB8B - SEC23A - SLC16A1 - SNX4 - TESC - VCL - ZNF160
innate immune response GO:0045087 Annotated genes: 710 Significant regulated genes: 66	ADAR - AGER - ANXA1 - APOL1 - AQP4 - B2M - BIRC3 - BPIFB1 - BST2 - C1RL - C3 - CASP4 - CCL20 - CD177 - CFB - CFD - CLU - CREBBP - CSK - CXCL16 - DDX3X - DTX3L - EIF2AK2 - GBP1 - GBP4 - GSDMD - HLA-B - HLA-	ARID5A - C6 - EPRS - ERAP1 - GAPDH - LTF - POLR3D - PPP1R14B
p-value: 1.2 · 10 ⁻⁶	C - HLA-DPB1 - HSPA1A - ICAM1 - IFI35 - IFI6 - IFIT1 - IFIT3 - IRF1 - IRF2 - IRF7 - ISG15 - LCN2 - MUC1 - MUC5B - MUL1 - MX1 - MX2 - OAS3 - PARP9 - PLSCR1 - RSAD2 - SLPI - STAT1 - TBK1 - TNFAIP3 - TRIM25 - TRIM56 - TYROBP - VAMP3 - XAF1	
antimicrobial humoral respon GO:0019730 Annotated genes: 71 Significant regulated genes: 9 p-value: 0.00951	se BPIFB1 - CLU - DCD - LCN2 - SLPI - SPINK5	GAPDH - LTF - LYZ

Supplemental Table S5: List of significantly regulated genes displayed in the GO circle in Figure 5E.

positive regulation of I-kappa	B kinase/NF-kappaB signaling	
GO:0043123 Annotated genes: 154 Significant regulated genes: 13 p-value: 0.04993	BIRC3 - BST2 - CARD16 - CFLAR - LTBR - MUL1 - SECTM1 - SHISA5 - TBK1 - TNFSF10 - TRIM25	FKBP1A - LTF
extracellular space		
GO:0005615 Annotated genes: 2468 Significant regulated genes: 195 p-value: 5.5 · 10 ⁻¹²	ADIRF - AHCTF1 - ALDH3B1 - ANXA1 - APOC1 - APOD - APOE - APOL1 - APPL2 - B2M - BPIFB1 - BST2 - C1RL - C3 - CA4 - CCL20 - CD177 - CD48 - CD82 - CFB - CFD - CLU - COBLL1 - CPNE8 - CRNN - CSF3 - CSK - CTSH - CXCL1 - CXCL16 - CXCL2 - DCD - DDX3X - DLK1 - DNAJA1 - DNAJB1 - EPCAM - EPHB4 - FGF18 - FRZB - GPIHBP1 - GPM6A - GSDMD - HIST1H2AC - HLA- B - HLA-C - HP - HPR - HSPA1A - HSPA6 - HSPH1 - ICAM1 - IDH1 - IGFBP4 - JADE2 - KRT19 - LAP3 - LAT2 - LCN2 - LGI4 - LRG1 - LRRC57 - LTB - MAL2 - MAN1A1 - MEST - MSMB - MUC1 - MUC5B - N4BP2L2 - NAPSA - OAS3 - PARP4 - PLSCR1 - PPBP - PRSS8 - PSCA - PSMB9 - PTPRD - RAB34 - RAPGEF3 - RHOF - SCGB3A1 - SECTM1 - SFN - SFTPB - SLC2A3 - SLPI - SORL1 - SPN - SRI - STX2 - TF - TM7SF3 - TNFAIP3 - TNFAIP6 - TNFSF10 - TNFSF14 - TPM3	ABI1 - ACTN1 - ACTN2 - ADA2 - ADGRE5 - ALDOA - ANO6 - ARPC1A - ATP1B1 - ATP5F1A - ATP5F1B - AZGP1 - BGN - C6 - CD63 - CDH13 - CKB - COL1A1 - COL1A2 - CRYAB - CS - CSE1L - CYB5R1 - CYFIP2 - DSP - DSTN - ENO3 - EPS8 - ERAP1 - EXOSC9 - F13A1 - F5 - FN1 - FUCA2 - GAPDH - GARS - GOT2 - HJV - HNRNPA1 - HSPA9 - IDH2 - IL33 - KALRN - LACRT - LAMC1 - LCN1 - LOXL1 - LTF - LYZ - MB - MGP - NAPG - NCL - NEBL - NPPA - NPPB - OPRPN - PACSIN3 - PDCD5 - PGK1 - PIP - POSTN - PRDX6 - RAB21 - RAB8B - RHOB - RHOQ - RPL12 - RPLP2 - RPS8 - RSU1 - SCGB1D1 - SCGB2A1 - SLC16A1 - SLC25A3 - SMPD1 - SMS - SND1 - SOD3 - THNSL2 - TIMM8B - TIMP1 - TMEM256 - TNC - TTN - UBE2D2 - UBE2G1 - VCL - VDAC1 - VPS4A - WWP1 - YWHAG
	- VASHI - VEGFD - WARS - WFDC2	
extracellular exosome GO:0070062 Annotated genes: 1834 Significant regulated genes: 153 p-value: $4.4 \cdot 10^{-11}$	ADIRF - AHCTF1 - ALDH3B1 - ANXA1 - APOD - APOE - APPL2 - B2M - BPIFB1 - BST2 - C1RL - C3 - CA4 - CD177 - CD48 - CD82 - CFB - CFD - CLU - COBLL1 - CPNE8 - CRNN - CSK - CTSH - DCD - DDX3X - DNAJA1 - DNAJB1 - EPCAM - EPHB4 - GPM6A - HIST1H2AC - HLA-B - HLA-C - HP - HPR - HSPA1A - HSPA6 - HSPH1 - ICAM1 - IDH1 - JADE2 - KRT19 - LAP3 - LAT2 - LCN2 - LRG1 - LRRC57 - MAL2 - MAN1A1 - MEST - MUC1 - MUC5B - N4BP2L2 - NAPSA - PARP4 - PLSCR1 - PRSS8 - PSCA - PSMB9 - PTPRD - RAB34 - RAPGEF3 - RHOF - SCGB3A1 - SECTM1 - SFN - SLC2A3 - SLPI - SORL1 - SPN - SRI - TF - TM7SF3 - TNFAIP3 - TNFSF10 - TPM3 - WARS - WFDC2	ABI1 - ACTN1 - ACTN2 - ADGRE5 - ALDOA - ANO6 - ARPC1A - ATP1B1 - ATP5F1A - ATP5F1B - AZGP1 - BGN - C6 - CD63 - CDH13 - CKB - COL1A2 - CRYAB - CS - CSE1L - CYB5R1 - CYFIP2 - DSP - DSTN - ENO3 - EPS8 - ERAP1 - EXOSC9 - FN1 - FUCA2 - GAPDH - GARS - GOT2 - HNRNPA1 - HSPA9 - IDH2 - KALRN - LAMC1 - LTF - LYZ - MB - MGP - NAPG - NCL - NEBL - PACSIN3 - PDCD5 - PGK1 - PIP - PRDX6 - RAB21 - RAB8B - RHOB - RHOQ - RPL12 - RPLP2 - RPS8 - RSU1 - SLC16A1 - SLC25A3 - SMPD1 - SMS - SND1 - SOD3 - TIMP1 - TMEM256 - TTN - UBE2D2 - UBE2G1 - VCL - VDAC1 - VPS4A - WWP1 - YWHAG
collagen-containing extracell	ular matrix	
GO:0062023 Annotated genes: 219 Significant regulated genes: 23 p-value: 0.00063	APUE - CLU - CUL27A1 - ICAM1 - LAMB3 - SBSPUN - SLPI	ASPN - AZGP1 - BGN - CCDC80 - CDH13 - COL1A1 - COL1A2 - FN1 - LAMC1 - LOXL1 - MGP - NPPA - POSTN - SOD3 - TIMP1 - TNC
blood microparticle GO:0072562 Annotated genes: 100	APOE - APOL1 - C3 - CFB - CLU - HP - HPR - HSPA1A - HSPA6 - TF	F13A1 - FN1

Significant regulated genes: 12 p-value: 0.00415		
mitochondrion		
GO:0005739 Annotated genes: 1454 Significant regulated genes: 112 p-value: 1.8 · 10 ⁻⁶	ABCA8 - ABCG1 - ANXA1 - ATAD3B - ATP5PD - BAG5 - BRAF - CASP4 - CLU - DDX3X - DNAJA1 - GOS2 - HIF3A - HSPA1A - IDH1 - IFI6 - IFIT3 - MIGA2 - MIPEP - MTERF2 - MUL1 - MX1 - MX2 - MXD1 - PARP9 - RSAD2 - SCO2 - SFN - SLC25A28 - SLC8B1 - SRI - TK2 - TYMP - UBIAD1 - WDR81 - XAF1	AFG3L2 - APEX1 - APEX2 - ATP5F1A - ATP5F1B - ATP5MC3 - ATP5MG - ATP5MPL - ATP5PF - ATPAF1 - BCKDK - BNIP3 - BOLA3 - CARD19 - CHCHD10 - CHPF - CKMT2 - COX4I1 - COX5B - COX6A2 - COX6B1 - COX6C - CREB3L4 - CRYAB - CS - CYB5R1 - DLD - DNM1L - ECHS1 - ETFA - ETFB - FAM162A - FECH - GARS - GATD3A - GOT2 - GSK3B - HADH - HADHB - HK1 - HSPA9 - IDH2 - IDH3G - LDHD - MLYCD - MRPL13 - MRPL15 - MRPL32 - MRPS12 - MRPS17 - MRPS33 - MSRB2 - NAPG - NDRG4 - NDUFA10 - NDUFA9 - NDUFB1 - NDUFB8 - NDUFS1 - NDUFS3 - NDUFV2 - NDUFV3 - NOC3L - PLIN5 - PRELID3B - SLC25A12 - SLC25A3 - SLC25A4 - TCHP - TIMM17A - TIMM8B - TRIT1 - UQCRFS1 - UQCRH - VDAC1 - YWHAG
identical protein binding		
GO:0042802	ABCG1 - ADD2 - AGER - ANXA1 - APOE - ARL6IP1 - B2M - BCL6 - BRAF -	ACTN1 - ACTN2 - ADA2 - ALDOA - ANO6 - APCDD1 - BNIP3 - CAP2 -
Annotated genes: 1476	BRCA2 - BST2 - CARD16 - CLDN15 - CLDN4 - COIL - CRLF3 - CSK - EIF2AK2	CBY1 - CDH13 - COL1A1 - COL1A2 - CRYAB - CSRP3 - DAPK2 - DNM1L -
Significant regulated genes: 96	- GBP1 - GBP4 - ID1 - IDH1 - IFIT3 - IL6R - LTBR - MIGA2 - MMACHC - MUL1	ENO3 - EPRS - ESYT2 - FHL2 - FKBP1A - FN1 - GAPDH - GARS - GNPNAT1
p-value: 0.00842	- MVD - MX1 - MZF1 - RB1 - SFN - SLC8B1 - SRGAP2C - STAT1 - TAP1 - TBK1	- GOT2 - HK1 - HSPB6 - HSPB8 - KCNK1 - LYZ - MLYCD - MTUS2 - NCL -
	- TMEM192 - TNFAIP3 - TNFSF10 - TYROBP - TYRP1 - VEGFD - WARS	PLIN5 - PRDX6 - PRKRA - PSME3 - RPL7 - SLC16A1 - SLC25A12 - TENM2 - TERF2 - TESC - TNNC1 - TPM1 - TPM2 - TTN - USP2 - VDAC1 - YWHAG
regulation of apoptotic proces	SS	
GO:0042981	ADAR - ANXA1 - APOE - ARHGEF1 - ARL6IP1 - BAG5 - BCL6 - BIRC3 - BRAF	AAMDC - ACTN1 - ACTN2 - ANKRD1 - ANO6 - APEX1 - BNIP3 - CDC73 -
Annotated genes: 1314	- CARD16 - CASP4 - CFLAR - CLU - CREBBP - CTSH - DDX3X - DEDD2 -	CDKN1A - CRYAB - DAB2 - DAPK2 - DNM1L - EGLN3 - FAM162A - FHL2
Significant regulated genes: 84	DHCR24 - DNAJA1 - EIF2AK2 - FRZB - GOS2 - GRINA - HSPA1A - HSPH1 -	- GAPDH - GSK3B - HSPA9 - HSPB6 - ITSN1 - KALRN - LACRT - LTF -
p-value: 0.0155	ICAM1 - ID1 - IFI6 - IFIT3 - INPP5D - IRF7 - KCNB1 - LTBR - MUC1 - MUL1 -	MLLT11 - NDUFS3 - PDCD5 - PDE3A - PIP - PRKRA - PSME3 - QRICH1 -
	NUPR1 - SFN - STAT1 - TNFAIP3 - TNFRSF10A - TNFRSF14 - TNFRSF1B - TNFSF10 - TNFSF14	RETREG1 - RHOB - RRN3 - SH3RF2 - SMPD1 - SRSF6 - TIMP1 - YWHAG

60 torm information	Significantly unregulated genes	Significantly downrogulated genes
Goterminormation		Significantiy downlegulated genes
type I interferon signaling pat GO:0060337 Annotated genes: 69 Significant regulated genes: 19 p-value: 8.5 · 10 ⁻¹⁰	hway ADAR - BST2 - HLA-B - HLA-C - IFI35 - IFI6 - IFIT1 - IFIT3 - IRF1 - IRF2 - IRF7 - ISG15 - MUL1 - MX1 - MX2 - OAS3 - RSAD2 - STAT1 - XAF1	-
defense response to virus GO:0051607 Annotated genes: 190 Significant regulated genes: 29 p-value: $1.0 \cdot 10^{-7}$	ADAR - BIRC3 - BST2 - DTX3L - EIF2AK2 - GBP1 - IFI44L - IFIT1 - IFIT3 - IRF1 - IRF2 - IRF7 - ISG15 - MUL1 - MX1 - MX2 - OAS3 - PARP9 - PLSCR1 - RNF26 - RSAD2 - STAT1 - TBK1 - TNFAIP3 - TRIM25 - TRIM56	BNIP3 - IL33 - POLR3D
negative regulation of viral ge	nome replication	
GO:0045071 Annotated genes: 47 Significant regulated genes: 13 p-value: $3.8 \cdot 10^{-7}$	ADAR - BST2 - EIF2AK2 - IFIT1 - ISG15 - MX1 - OAS3 - PARP10 - PLSCR1 - PROX1 - RSAD2 - SLPI	LTF
extracellular exosome		
GO:0070062 Annotated genes: 1834 Significant regulated genes: 153 p-value: 4.4 · 10 ⁻¹¹	ADIRF - AHCTF1 - ALDH3B1 - ANXA1 - APOD - APOE - APPL2 - B2M - BPIFB1 - BST2 - C1RL - C3 - CA4 - CD177 - CD48 - CD82 - CFB - CFD - CLU - COBLL1 - CPNE8 - CRNN - CSK - CTSH - DCD - DDX3X - DNAJA1 - DNAJB1 - EPCAM - EPHB4 - GPM6A - HIST1H2AC - HLA-B - HLA-C - HP - HPR - HSPA1A - HSPA6 - HSPH1 - ICAM1 - IDH1 - JADE2 - KRT19 - LAP3 - LAT2 - LCN2 - LRG1 - LRRC57 - MAL2 - MAN1A1 - MEST - MUC1 - MUC5B - N4BP2L2 - NAPSA - PARP4 - PLSCR1 - PRSS8 - PSCA - PSMB9 - PTPRD - RAB34 - RAPGEF3 - RHOF - SCGB3A1 - SECTM1 - SFN - SLC2A3 - SLPI - SORL1 - SPN - SRI - TF - TM7SF3 - TNFAIP3 - TNFSF10 - TPM3 - WARS - WFDC2	ABI1 - ACTN1 - ACTN2 - ADGRE5 - ALDOA - ANO6 - ARPC1A - ATP1B1 - ATP5F1A - ATP5F1B - AZGP1 - BGN - C6 - CD63 - CDH13 - CKB - COL1A2 - CRYAB - CS - CSE1L - CYB5R1 - CYFIP2 - DSP - DSTN - ENO3 - EP58 - ERAP1 - EXOSC9 - FN1 - FUCA2 - GAPDH - GARS - GOT2 - HNRNPA1 - HSPA9 - IDH2 - KALRN - LAMC1 - LTF - LYZ - MB - MGP - NAPG - NCL - NEBL - PACSIN3 - PDCD5 - PGK1 - PIP - PRDX6 - RAB21 - RAB8B - RHOB - RHOQ - RPL12 - RPLP2 - RPS8 - RSU1 - SLC16A1 - SLC25A3 - SMPD1 - SMS - SND1 - SOD3 - TIMP1 - TMEM256 - TTN - UBE2D2 - UBE2G1 - VCL - VDAC1 - VPS4A - WWP1 - YWHAG
enzyme inhibitor activity		
GO:0004857 Annotated genes: 322 Significant regulated genes: 32	ANXA1 - APOC1 - BIRC3 - BST2 - C3 - CARD16 - DTX3L - PARP9 - PDE6G - SAG - SFN - SLPI - SPINK5 - TF - TNFSF14 - WARS - WFDC2	ASPN - BGN - CDKN1A - GAPDH - LCN1 - LTF - OPRPN - PKIA - PKIG - PPP1R14B - SH3RF2 - SLN - TESC - TIMP1 - YWHAG
inner mitochondrial membrar	ne protein complex	
GO:0098800 Annotated genes: 130	АТРБРД	AFG3L2 - ATP5F1A - ATP5F1B - ATP5MC3 - ATP5MG - ATP5MPL - ATP5PF - COX4I1 - COX5B - COX6A2 - NDUFA10 - NDUFA9 - NDUFB1 -

Supplemental Table S6: List of significantly regulated genes displayed in the GO circle in Figure 6A.

Significant regulated genes: 22 p-value: 4.6 · 10 ⁻⁷		NDUFB8 - NDUFS1 - NDUFS3 - NDUFV2 - NDUFV3 - TIMM17A - UQCRFS1 - UQCRH
proton transmembrane trans	sporter activity	
GO:0015078	ATP5PD - SLC17A5	ATP5F1A - ATP5F1B - ATP5MC3 - ATP5MG - ATP5PF - COX4I1 - COX5B
Annotated genes: 102		- COX6A2 - COX6B1 - COX6C - SLC25A3 - SLC9A8
Significant regulated genes: 14		
p-value: 0.0007		
NADH dehydrogenase (ubiqu	inone) activity	
GO:0008137	-	NDUFA10 - NDUFA9 - NDUFB1 - NDUFB8 - NDUFS1 - NDUFS3 -
Annotated genes: 43		NDUFV2 - NDUFV3
Significant regulated genes: 8		
p-value: 0.00136		
Z disc		
GO:0030018	KRT19 - MYBPC1 - SRI	ACTN1 - ACTN2 - CACNA1C - CRYAB - CSRP3 - FBXO32 - FHL2 - FHOD3
Annotated genes: 146		- FKBP1A - FLNC - HRC - ITGB1BP2 - MYH7 - MYPN - MYZAP - NEBL -
Significant regulated genes: 25		NEXN - PARVB - PDLIM3 - PPP1R12B - TCAP - TTN
p-value: 4.3 · 10 ⁻¹⁰		
structural constituent of mus	scle	
GO:0008307	KRT19 - MYBPC1 - TPM3	ACTN2 - CSRP3 - NEBL - NEXN - TCAP - TPM1 - TPM2 - TTN
Annotated genes: 40		
Significant regulated genes: 11		
p-value: 3.6 · 10 ⁻⁶		
actin filament binding		
GO:0051015	ADD2 - MYBPC1 - TPM3	ACTN1 - ACTN2 - ARPC1A - DSTN - FLNC - MYH7 - MYPN - NEBL - NEXN
Annotated genes: 150		- TNNC1 - TPM1 - TPM2 - TTN - VCL
Significant regulated genes: 17		
p-value: 0.00179		

GO term information	Significantly upregulated genes	Significantly downregulated genes		
defense response to virus				
GO:0051607	ADAR - BIRC3 - BST2 - DTX3L - EIF2AK2 - GBP1 - IFI44L - IFIT1 - IFIT3 - IRF1	BNIP3 - IL33 - POLR3D		
Annotated genes: 190	- IRF2 - IRF7 - ISG15 - MUL1 - MX1 - MX2 - OAS3 - PARP9 - PLSCR1 - RNF26			
Significant regulated genes: 39	- RSAD2 - STAT1 - TBK1 - TNFAIP3 - TRIM25 - TRIM56			
p-value: 1.0 · 10 ⁻⁷				
response to virus				
GO:0009615	ADAR - BIRC3 - BST2 - CLU - DDX3X - DTX3L - EIF2AK2 - GBP1 - IFI44 - IFI44L	BNIP3 - DDX1 - DDX21 - IL33 - POLR3D - PRKRA		
Annotated genes: 265	- IFIT1 - IFIT3 - IRF1 - IRF2 - IRF7 - ISG15 - MUL1 - MX1 - MX2 - OAS3 -			
Significant regulated genes: 35	PARP9 - PLSCR1 - RNF26 - RSAD2 - STAT1 - TBK1 - TNFAIP3 - TRIM25 -			
p-value: 2.0 · 10 ⁻⁷	TRIM56			
negative regulation of viral g	enome replication			
GO:0045071	ADAR - BST2 - EIF2AK2 - IFIT1 - ISG15 - MX1 - OAS3 - PARP10 - PLSCR1 -	LTF		
Annotated genes: 47	PROX1 - RSAD2 - SLPI			
Significant regulated genes: 13				
p-value: 3.8 · 10 ⁻⁷				
negative regulation of viral li	fe cycle			
GO:1903901	ADAR - BST2 - EIF2AK2 - IFIT1 - ISG15 - MX1 - OAS3 - PARP10 - PLSCR1 -	LTF		
Annotated genes: 65	PROX1 - RSAD2 - SLPI - TRIM25			
Significant regulated genes: 14				
p-value: 3.7 · 10 ⁻⁶				
negative regulation of viral process				
GO:0048525	ADAR - BST2 - EIF2AK2 - IFIT1 - ISG15 - MX1 - OAS3 - PARP10 - PLSCR1 -	LTF		
Annotated genes: 76	PROX1 - RSAD2 - SLPI - STAT1 - TRIM25			
Significant regulated genes: 15				
p-value: 5.2 · 10 ⁻⁶				
regulation of viral genome replication				
GO:0045069	ADAR - BST2 - DDX3X - EIF2AK2 - IFIT1 - ISG15 - MX1 - OAS3 - PARP10 -	LTF		
Annotated genes: 79	PLSCR1 - PROX1 - RSAD2 - SLPI			
Significant regulated genes: 14				
p-value: 3.9 · 10⁻⁵				
regulation of viral process				
GO:0050792	ADAR - APOE - BST2 - DDX3X - EIF2AK2 - GTF2B - IFIT1 - ISG15 - MX1 -	LTF - VPS4A		
Annotated genes: 154	OAS3 - PARP10 - PLSCR1 - PROX1 - RSAD2 - SLPI - STAT1 - TRIM25			

Supplemental Table S7: List of significantly regulated genes displayed in the GO circle in Figure 6E: response to virus.

Supplemental Material

Lindner et al.

Significant regulated genes: 19		
p-value: 0.0003		
regulation of viral life cycle		
GO:1903900	ADAR - BST2 - DDX3X - EIF2AK2 - IFIT1 - ISG15 - MX1 - OAS3 - PARP10 -	LTF - VPS4A
Annotated genes: 119	PLSCR1 - PROX1 - RSAD2 - SLPI - TRIM25	
Significant regulated genes: 16		
p-value: 0.00033		
viral process		
GO:0016032	ADAR - APOE - AZI2 - B2M - BST2 - CFLAR - CREBBP - CUL5 - DDX3X - E4F1	ABI1 - AP1S2 - BNIP3 - CPSF4 - EIF3G - ELOC - HNRNPA1 - ITSN1 -
Annotated genes: 633	- EIF2AK2 - GTF2B - HLA-B - HLA-C - HSPA1A - ICAM1 - IFIT1 - IRF7 - ISG15	KPNA4 - LTF - MORC3 - SLC25A4 - SND1 - VDAC1 - VPS4A - WWP1
Significant regulated genes: 52	- KRT19 - LTBR - MX1 - OAS3 - PARP10 - PLSCR1 - PROX1 - PSMB9 - RB1 -	
p-value: 0.00041	RSAD2 - SLPI - STAT1 - TAF1 - TAP1 - TBK1 - TNFRSF14 - TRIM25	
viral genome replication		
GO:0019079	ADAR - BST2 - DDX3X - EIF2AK2 - IFIT1 - ISG15 - MX1 - OAS3 - PARP10 -	LTF
Annotated genes: 105	PLSCR1 - PROX1 - RSAD2 - SLPI	
Significant regulated genes: 14		
p-value: 0.00084		
regulation of defense response	se to virus by host	
GO:0050691	DTX3L - IFIT1 - MUL1 - PARP9 - STAT1 - TNFAIP3	-
Annotated genes: 33		
Significant regulated genes: 6		
p-value: 0.00575		
regulation of defense response	se to virus	
GO:0050688	BIRC3 - DTX3L - IFIT1 - MUL1 - PARP9 - RNF26 - STAT1 - TNFAIP3	-
Annotated genes: 64		
Significant regulated genes: 8		
p-value: 0.01528		
viral life cycle		
GO:0019058	ADAR - APOE - BST2 - DDX3X - EIF2AK2 - HSPA1A - ICAM1 - IFIT1 - ISG15 -	LTF - VPS4A - WWP1
Annotated genes: 259	MX1 - OAS3 - PARP10 - PLSCR1 - PROX1 - RSAD2 - SLPI - TNFRSF14 -	
Significant regulated genes: 21	TRIM25	
p-value: 0.02344		

GO term information	Significantly upregulated genes	Significantly downregulated genes
platelet alpha granule lumen		
GO:0031093	CFD - CLU - PPBP - VEGFD	ACTN1 - ACTN2 - ALDOA - F13A1 - F5 - FN1 - TIMP1
Annotated genes: 63		
Significant regulated genes: 11		
p-value: 0.00026		
platelet degranulation		
GO:0002576	CFD - CLU - PPBP - TF - VEGFD	ACTN1 - ACTN2 - ALDOA - CD63 - CYB5R1 - F13A1 - F5 - FN1 - TIMP1 -
Annotated genes: 118		TTN - VCL
Significant regulated genes: 16		
p-value: 0.0003		
platelet alpha granule		
GO:0031091	CFD - CLU - PPBP - VEGFD	ACTN1 - ACTN2 - ALDOA - CYB5R1 - F13A1 - F5 - FN1 - TIMP1
Annotated genes: 86		
Significant regulated genes: 11		
p-value: 0.00026		
complement activation, alter	rnative pathway	
GO:0006957	C3 - CFB - CFD	-
Annotated genes: 13		
Significant regulated genes: 3		
p-value: 0.02548		
high-density lipoprotein part	icle	
GO:0034364	APOC1 - APOE - APOL1 - CLU - GPIHBP1 - HPR	-
Annotated genes: 21		
Significant regulated genes: 6		
p-value: 0.00044		
lipoprotein particle / plasma lipoprotein particle		
GO:1990777 / GO:0034358	APOC1 - APOE - APOL1 - CLU - GPIHBP1 - HPR - SORL1	-
Annotated genes: 33		
Significant regulated genes: 7		
p-value: 0.00104		
lipoprotein particle binding		
GO:0071813	APOE - GPIHBP1 - SORL1	CDH13
Annotated genes: 22		

Supplemental Table S8: List of significantly regulated genes displayed in the GO circle in Figure 6F: on the right side platelet & complement / on the left side lipoproteins.

Significant regulated genes: 4 p-value: 0.02411				
high-density lipoprotein particle remodeling				
GO:0034375	ABCG1 - APOC1 - APOE			
Annotated genes: 14				
Significant regulated genes: 3				
p-value: 0.03123				
very-low-density lipoproteir	n particle / triglyceride-rich plasma lipoprotein particle			
GO:0034361 / GO:0034385	APOC1 - APOE - APOL1 -			
Annotated genes: 16				
Significant regulated genes: 3				
p-value: 0.0429				

Supplemental Table S9: List of significantly regulated genes displayed in the GO circle in Figure 6G: MHC antigene presentation.

GO term information	Significantly upregulated genes	Significantly downregulated genes		
MHC protein complex				
GO:0042611	B2M - HLA-B - HLA-C - HLA-DMA - HLA-DPB1 - HLA-E	-		
Annotated genes: 22				
Significant regulated genes: 6				
p-value: 0.00057				
MHC protein binding				
GO:0042287	PILRB - TAP1	ATP5F1A - ATP5F1B		
Annotated genes: 24				
Significant regulated genes: 4				
p-value: 0.03231				
antigen processing and presentation	of peptide antigen via MHC class I			
GO:0002474	B2M - HLA-B - HLA-C - HLA-E - TAP1 - VAMP3	ERAP1 - SEC23A		
Annotated genes: 45				
Significant regulated genes: 8				
p-value: 0.00173				
MHC class I protein binding				
GO:0042288	PILRB - TAP1	ATP5F1A - ATP5F1B		
Annotated genes: 15				
Significant regulated genes: 4				
p-value: 0.00598				
antigen processing and presentation	of exogenous peptide antigen via MHC class I, TAP-depende	ent		
GO:0002479	B2M - HLA-B - HLA-C - TAP1 - VAMP3	-		
Annotated genes: 24				
Significant regulated genes: 5				
p-value: 0.00633				
antigen processing and presentation of exogenous peptide antigen via MHC class I				
GO:0042590	B2M - HLA-B - HLA-C - TAP1 - VAMP3	-		
Annotated genes: 28				
Significant regulated genes: 5				
p-value: 0.01238				

3 References

- 1. Escher F, Kuhl U, Lassner D, Stroux A, Westermann D, Skurk C, Tschope C, Poller W and Schultheiss HP. Presence of perforin in endomyocardial biopsies of patients with inflammatory cardiomyopathy predicts poor outcome. *Eur J Heart Fail*. 2014;16:1066-72. doi: 10.1002/ejhf.148.
- Filbin MR, Mehta A, Schneider AM, Kays KR, Guess JR, Gentili M, Fenyves BG, Charland NC, Gonye ALK, Gushterova I, Khanna HK, LaSalle TJ, Lavin-Parsons KM, Lilly BM, Lodenstein CL, Manakongtreecheep K, Margolin JD, McKaig BN, Rojas-Lopez M, Russo BC, Sharma N, Tantivit J, Thomas MF, Gerszten RE, Heimberg GS, Hoover PJ, Lieb DJ, Lin B, Ngo D, Pelka K, Reyes M, Smillie CS, Waghray A, Wood TE, Zajac AS, Jennings LL, Grundberg I, Bhattacharyya RP, Parry BA, Villani AC, Sade-Feldman M, Hacohen N and Goldberg MB. Plasma proteomics reveals tissue-specific cell death and mediators of cell-cell interactions in severe COVID-19 patients. *bioRxiv*. 2020. doi: 10.1101/2020.11.02.365536.